Phillip Smith is the Director of Process Technology in the GSK Biopharm R&D Clinical
Manufacturing Pilot Plant in King of Prussia, PA. He leads a team of Scientists who conduct
technology transfer, facility fit, scale-up, and troubleshooting activities for drug substance
manufacturing processes. Other responsibilities include authoring of regulatory
submissions and industrialization of new processing technologies. Previous roles include
late-phase process development, characterization, and control strategy development for
downstream unit operations in GSK Biopharm R&D, and early-phase downstream process
development and technology transfer at Bristol-Myers Squibb. Phil is also a leader in
Quality by Design practice within GSK and a member of the Biopharm Sustainability Team.
He regularly presents at industry conferences and participates in various industry
consortia. Phil received B.S. and M.S. degrees in Chemical Engineering from Brigham
Young University, and a PhD degree in Chemical Engineering from Stanford University.
In the bustling city of Boston, amidst the vibrant biotech community, the 2024 ISPE Biotechnology Conference will gather industry leaders and innovators for a pivotal set of discussions on Track 4: Lifecycle...
The 2024 ISPE Biotechnology Conference will be held 17–18 June in Boston, Massachusetts, and virtually. Phillip R. Smith is the conference’s Planning Chair. He shares what attendees can expect at the upcoming...
The biotechnology industry continues to evolve, advancing the frontiers of science and engineering in the design, development, and manufacture of a wide variety of therapeutic modalities. Advances in cell and gene therapies continue to offer treatments for diseases that were previously uncurable, with seven approvals in 2023, including treatments for sickle-cell disease, hemophilia, type 1...
Are you interested in developing a new bioproduct and attracted by the incredible potentials of new modalities like ATMPs, Cell and Gene Therapies, AAVs, oligonucleotides, multi-specificity antibodies, mRNA vaccines, and more? Despite the appeal of these new modalities, there is a significant risk of failure due to the many unknowns associated with these new technologies.
Digital transformation has been growing in importance and urgency as the biopharma and biotech industry, manufacturers, and service providers seek to accelerate build-out of facilities and manufacturing processes in support of advanced biotherapeutics.